Key Points
- Director Cheryl Scott sold 7,439 Progyny shares on June 1 at an average price of $26.39, totaling about $196,315. Following the sale, she still owned 19,772 shares, a 27.34% reduction in her stake.
- Progyny’s latest results beat expectations, with quarterly EPS of $0.50 versus the $0.26 consensus estimate and revenue of $328.5 million slightly above forecasts. However, revenue was still down 26.4% year over year.
- The company authorized a $200 million share buyback, covering up to 10.3% of outstanding shares, while analysts maintain a Moderate Buy consensus with an average price target of $29.67.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) insider Geoffrey Clapp sold 1,530 shares of the company's stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the transaction, the insider directly owned 59,117 shares of the company's stock, valued at $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Progyny Price Performance
PGNY stock opened at $24.99 on Thursday. The stock has a market capitalization of $1.96 billion, a P/E ratio of 32.45, a P/E/G ratio of 1.34 and a beta of 1.03. The business has a 50-day moving average of $20.27 and a 200-day moving average of $22.26. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $28.75.
Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.24. The company had revenue of $328.50 million during the quarter, compared to analysts' expectations of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny's revenue for the quarter was down 26.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts expect that Progyny, Inc. will post 1.12 EPS for the current year.
Progyny declared that its board has authorized a stock repurchase program on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Progyny in the 4th quarter valued at about $25,000. Federated Hermes Inc. lifted its stake in Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company's stock valued at $30,000 after purchasing an additional 819 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company's stock valued at $43,000 after purchasing an additional 742 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in Progyny in the 2nd quarter valued at about $77,000. Finally, Quarry LP lifted its stake in Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company's stock valued at $77,000 after purchasing an additional 3,427 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on PGNY shares. BTIG Research reduced their price objective on Progyny from $35.00 to $30.00 and set a "buy" rating for the company in a research report on Thursday, March 5th. Citizens Jmp upped their price objective on Progyny from $30.00 to $31.00 and gave the stock a "market outperform" rating in a research report on Monday, May 11th. Truist Financial increased their price target on Progyny from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Weiss Ratings reissued a "hold (c)" rating on shares of Progyny in a research report on Friday, March 27th. Finally, Zacks Research raised Progyny from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.67.
Get Our Latest Analysis on Progyny
Progyny Company Profile
(
Get Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
